Humacyte (NASDAQ:HUMA) Trading Down 5.8% – Time to Sell?

Humacyte, Inc. (NASDAQ:HUMA) dropped 5.8% during mid-day trading on Monday . The company traded as low as $5.12 and last traded at $5.18. Approximately 3,711,508 shares were traded during trading, an increase of 31% from the average daily volume of 2,841,564 shares. The stock had previously closed at $5.50.

Analyst Ratings Changes

A number of research firms have weighed in on HUMA. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Friday, December 20th. TD Cowen reissued a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. Finally, Benchmark increased their price target on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Trading Down 0.8 %

The firm has a 50-day simple moving average of $4.76 and a 200-day simple moving average of $5.72. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The stock has a market cap of $635.59 million, a PE ratio of -3.77 and a beta of 1.38.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 261,369 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the sale, the chief executive officer now directly owns 1,730,884 shares in the company, valued at $7,615,889.60. This represents a 13.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,500,000 shares of company stock valued at $6,606,799. Corporate insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently modified their holdings of HUMA. nVerses Capital LLC purchased a new stake in Humacyte in the second quarter valued at approximately $28,000. Concurrent Investment Advisors LLC purchased a new position in Humacyte in the third quarter worth $75,000. Principal Financial Group Inc. bought a new position in Humacyte in the second quarter valued at $83,000. FORA Capital LLC bought a new stake in Humacyte during the third quarter worth about $96,000. Finally, Profund Advisors LLC bought a new position in shares of Humacyte during the 2nd quarter valued at about $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.